Gebr Heinemann

Gebr Heinemann, headquartered in Germany and operating in the Pharmaceutical Preparation Manufacturing industry, reported its total greenhouse gas emissions for 2025 as approximately 102,322,000 kg CO2e. This includes Scope 1 emissions of about 3,310,000 kg CO2e, Scope 2 emissions of approximately 10,412,000 kg CO2e, and Scope 3 emissions totalling around 88,600,000 kg CO2e.

Looking at previous years, Gebr Heinemann's total emissions were approximately 104,769,000 kg CO2e in 2024, and about 85,679,000 kg CO2e in 2023. In 2019, the company's total emissions were approximately 158,335,000 kg CO2e, with Scope 1 at about 3,974,000 kg CO2e, Scope 2 at approximately 31,499,000 kg CO2e, and Scope 3 at around 122,862,000 kg CO2e.

Gebr Heinemann has demonstrated a strong commitment to climate action, aligning with the Science Based Targets initiative (SBTi) and the Paris Climate Agreement's 1.5-degree target. The company aims for net-zero emissions across its entire value chain by 2045.

Its near-term targets include reducing absolute Scope 1 and 2 greenhouse gas emissions by 95% by 2030, using a 2019 base year. Furthermore, Gebr Heinemann commits to reducing absolute Scope 3 GHG emissions by 50% within the same timeframe. For the long term, the company pledges to maintain a minimum of 95% absolute Scope 1 and 2 GHG emissions reductions from 2030 through to 2045, and to reduce absolute Scope 3 GHG emissions by 90% by 2045 from a 2019 base year.